Top

Open Access 05-09-2024 | Hepatocellular Carcinoma | RESEARCH ARTICLE

Potential prognostic biomarker SERPINA12: implications for hepatocellular carcinoma

Authors: Huan Yang, Panpan Kong, Songyu Hou, Xiaogang Dong, Imamumaimaitijiang Abula, Dong Yan

Published in: Clinical and Translational Oncology

Abstract

Background

Hepatocellular carcinoma (HCC) remains one of the most prevalent malignant tumors, exhibiting a high morbidity and mortality rate. The mechanism of its occurrence and development requires further study. The objective of this study was to investigate the role of SERPINA12 in the diagnosis, prognosis prediction and biological function within HCC.

Methods

The Cancer Genome Atlas (TCGA) data were employed to analyze the relationship between clinical features and SERPINA12 expression in HCC. Kaplan–Meier curves were utilized to analyze the correlation between SERPINA12 expression and prognosis in HCC. The function of SERPINA12 was determined by enrichment analysis, and the relationship between SERPINA12 expression and immune cell infiltration was investigated. The expression of SERPINA12 was examined in 75 patients with HCC using RT-qPCR and immunohistochemistry, and survival analysis was performed.

Results

The expression of SERPINA12 from TCGA database was found to be significantly higher in HCC tissues than in normal tissues and carried a poor prognosis. ROC curve demonstrated the diagnostic potential of SERPINA12 for HCC. The multivariate Cox regression analysis showed that pathologic T stage, tumor status, and SERPINA12 expression were independently associated with patient survival. The SERPINA12 expression was found to correlate with immune cell infiltration. Our RT-qPCR and immunohistochemical analysis revealed high expression of SERPINA12 in tumor tissues. Survival analysis indicated its association with poor prognosis.

Conclusion

SERPINA12 is a promising biomarker for diagnosis and prognosis, and it is associated with immune cell infiltration.

Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61. https://doi.org/10.1016/bs.acr.2020.10.001. (Epub 2020 Nov 28. PMID: 33579421; PMCID: PMC8796122).CrossRefPubMed

Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, Laversanne M, McGlynn KA, Soerjomataram I. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–606. https://doi.org/10.1016/j.jhep.2022.08.021. (Epub 2022 Oct 5. PMID: 36208844; PMCID: PMC9670241).CrossRefPubMedPubMedCentral

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021. https://doi.org/10.1002/ijc.33588. (Epub ahead of print. PMID: 33818764).CrossRefPubMed

Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev. 2023;42(3):629–52. https://doi.org/10.1007/s10555-023-10084-4. (Epub 2023 Feb 2 PMID: 36729264).CrossRefPubMed

Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig. 2015;21(1):57–74. https://doi.org/10.1515/hmbci-2014-0037. (PMID: 25781552).CrossRefPubMed

Tsai IT, Wang CP, Yu TH, Lu YC, Lin CW, Lu LF, Wu CC, Chung FM, Lee YJ, Hung WC, Hsu CC. Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection. Cytokine. 2017;90:54–9. https://doi.org/10.1016/j.cyto.2016.10.007. (Epub 2016 Oct 19 PMID: 27770715).CrossRefPubMed

Kurowska P, Mlyczyńska E, Dawid M, Jurek M, Klimczyk D, Dupont J, Rak A. Review: vaspin (SERPINA12) expression and function in endocrine cells. Cells. 2021;10(7):1710. https://doi.org/10.3390/cells10071710. (PMID:34359881;PMCID:PMC8307435).CrossRefPubMedPubMedCentral

Arab JP, Cabrera D, Sehrawat TS, Jalan-Sakrikar N, Verma VK, Simonetto D, Cao S, Yaqoob U, Leon J, Freire M, Vargas JI, De Assuncao TM, Kwon JH, Guo Y, Kostallari E, Cai Q, Kisseleva T, Oh Y, Arrese M, Huebert RC, Shah VH. Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12. J Hepatol. 2020;73(1):149–60. https://doi.org/10.1016/j.jhep.2020.02.005. (Epub 2020 Feb 20. PMID: 32087348; PMCID: PMC7305991).CrossRefPubMedPubMedCentral

Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H, Kanwar YS. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005;102(30):10610–5. https://doi.org/10.1073/pnas.0504703102. (Epub 2005 Jul 19. PMID: 16030142; PMCID: PMC1180799).CrossRefPubMedPubMedCentral

10.

Farahani H, Amri J, Alaee M, Mohaghegh F, Rafiee M. Serum and saliva levels of cancer antigen 15–3, carcinoembryonic antigen, estradiol, vaspin, and obestatin as biomarkers for the diagnosis of breast cancer in postmenopausal women. Lab Med. 2020;51(6):620–7. https://doi.org/10.1093/labmed/lmaa013. (PMID: 32537654).CrossRefPubMed

11.

Kozłowski M, Pietrzyk D, Rychlicka M, Piotrowska K, Nowak K, Kwiatkowski S, Cymbaluk-Płoska A. Evaluation of tissue expression of vaspin and serum vaspin concentration as a prognostic and risk factor in endometrial cancer. Cells. 2022;11(20):3196. https://doi.org/10.3390/cells11203196. (PMID:36291064;PMCID:PMC9600625).CrossRefPubMedPubMedCentral

12.

Bockorny B, Muthuswamy L, Huang L, Hadisurya M, Lim CM, Tsai LL, Gill RR, Wei JL, Bullock AJ, Grossman JE, Besaw RJ, Narasimhan S, Tao WA, Perea S, Sawhney MS, Freedman SD, Hidalgo M, Iliuk A, Muthuswamy SK. A large-scale proteomics resource of circulating extracellular vesicles for biomarker discovery in pancreatic cancer. medRxiv [Preprint]. 2023. https://doi.org/10.1101/2023.03.13.23287216. (PMID: 36993200; PMCID: PMC10055460).CrossRef

13.

Chakraborty E, Sarkar D. Emerging therapies for hepatocellular carcinoma (HCC). Cancers (Basel). 2022;14(11):2798. https://doi.org/10.3390/cancers14112798. (PMID:35681776;PMCID:PMC9179883).CrossRefPubMed

14.

Yang J, Pan G, Guan L, Liu Z, Wu Y, Liu Z, Lu W, Li S, Xu H, Ouyang G. The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels. Cancer Med. 2022;11(5):1357–70. https://doi.org/10.1002/cam4.4530. (Epub 2022 Jan 6. PMID: 34989144; PMCID: PMC8894689).CrossRefPubMedPubMedCentral

15.

McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73(Suppl 1):4–13. https://doi.org/10.1002/hep.31288. (Epub 2020 Nov 24. PMID: 32319693; PMCID: PMC7577946).CrossRefPubMed

16.

Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52(12):1898–907. https://doi.org/10.1038/s12276-020-00527-1. (Epub 2020 Dec 2. PMID: 33268834; PMCID: PMC8080814).CrossRefPubMedPubMedCentral

17.

Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book. 2018;23(38):262–79. https://doi.org/10.1200/EDBK_200939. (PMID: 30231359).CrossRef

18.

Pinna AD, Yang T, Mazzaferro V, De Carlis L, Zhou J, Roayaie S, Shen F, Sposito C, Cescon M, Di Sandro S, Yi-Feng H, Johnson P, Cucchetti A. Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma. Ann Surg. 2018;268(5):868–75. https://doi.org/10.1097/SLA.0000000000002889. (Erratum.In:AnnSurg.2019Apr;269(4):e59 PMID: 30080736).CrossRefPubMed

19.

Pivonello C, De Martino MC, Negri M, Cuomo G, Cariati F, Izzo F, Colao A, Pivonello R. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect Agent Cancer. 2014;20(9):27. https://doi.org/10.1186/1750-9378-9-27. (PMID:25225571;PMCID:PMC4164328).CrossRef

20.

Wang Y, Zhang Y, Mi J, Jiang C, Wang Q, Li X, Zhao M, Geng Z, Song X, Li J, Zuo L, Ge S, Zhang Z, Wen H, Wang Z, Su F. ANKFN1 plays both protumorigenic and metastatic roles in hepatocellular carcinoma. Oncogene. 2022;41(29):3680–93. https://doi.org/10.1038/s41388-022-02380-0. (Epub 2022 Jun 21. PMID: 35725908; PMCID: PMC9287179).CrossRefPubMedPubMedCentral

21.

Liang Y, Luo H, Zhang H, Dong Y, Bao Y. Oncogene delta/notch-like EGF-related receptor promotes cell proliferation, invasion, and migration in hepatocellular carcinoma and predicts a poor prognosis. Cancer Biother Radiopharm. 2018;33(9):380–6. https://doi.org/10.1089/cbr.2018.2460. (Epub 2018 Sep 20. PMID: 30235011; PMCID: PMC6241329).CrossRefPubMedPubMedCentral

22.

Tyson JJ, Novák B. Time-keeping and decision-making in the cell cycle. Interface Focus. 2022;12(4):20210075. https://doi.org/10.1098/rsfs.2021.0075. (PMID:35860005;PMCID:PMC9184962).CrossRefPubMedPubMedCentral

23.

Sun Y, Liu Y, Ma X, Hu H. The influence of cell cycle regulation on chemotherapy. Int J Mol Sci. 2021;22(13):6923. https://doi.org/10.3390/ijms22136923.PMID:34203270;PMCID:PMC8267727.CrossRefPubMedPubMedCentral

24.

Jamasbi E, Hamelian M, Hossain MA, Varmira K. The cell cycle, cancer development and therapy. Mol Biol Rep. 2022;49(11):10875–83. https://doi.org/10.1007/s11033-022-07788-1. (Epub 2022 Aug 5 PMID: 35931874).CrossRefPubMed

25.

Liu J, Peng Y, Wei W. Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends Cell Biol. 2022;32(1):30–44. https://doi.org/10.1016/j.tcb.2021.07.001. (Epub 2021 Jul 22. PMID: 34304958; PMCID: PMC8688170).CrossRefPubMed

26.

Forciniti S, Greco L, Grizzi F, Malesci A, Laghi L. Iron metabolism in cancer progression. Int J Mol Sci. 2020;21(6):2257. https://doi.org/10.3390/ijms21062257.PMID:32214052;PMCID:PMC7139548.CrossRefPubMedPubMedCentral

27.

Salnikow K. Role of iron in cancer. Semin Cancer Biol. 2021;76:189–94. https://doi.org/10.1016/j.semcancer.2021.04.001. (Epub 2021 Apr 24 PMID: 33901632).CrossRefPubMed

28.

Tang S, Ning Q, Yang L, Mo Z, Tang S. Mechanisms of immune escape in the cancer immune cycle. Int Immunopharmacol. 2020;86: 106700. https://doi.org/10.1016/j.intimp.2020.106700. (Epub 2020 Jun 23 PMID: 32590316).CrossRefPubMed

29.

Rameshbabu S, Labadie BW, Argulian A, Patnaik A. Targeting innate immunity in cancer therapy. Vaccines (Basel). 2021;9(2):138. https://doi.org/10.3390/vaccines9020138. (PMID:33572196;PMCID:PMC7916062).CrossRefPubMed

30.

Basu A, Ramamoorthi G, Albert G, Gallen C, Beyer A, Snyder C, Koski G, Disis ML, Czerniecki BJ, Kodumudi K. Differentiation and regulation of TH cells: a balancing act for cancer immunotherapy. Front Immunol. 2021;3(12): 669474. https://doi.org/10.3389/fimmu.2021.669474. (PMID:34012451;PMCID:PMC8126720).CrossRef

31.

Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol. 1999;21(3):339–59. https://doi.org/10.1007/BF00812261. (PMID: 10666777).CrossRefPubMed

32.

Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 2016;16(10):599–611. https://doi.org/10.1038/nri.2016.80. (Epub 2016 Aug 16 PMID: 27526640).CrossRefPubMed

33.

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44. https://doi.org/10.1038/nature07205. (PMID: 18650914).CrossRefPubMed

34.

Le L, Tokumaru Y, Oshi M, Asaoka M, Yan L, Endo I, Ishikawa T, Futamura M, Yoshida K, Takabe K. Th2 cell infiltrations predict neoadjuvant chemotherapy response of estrogen receptor-positive breast cancer. Gland Surg. 2021;10(1):154–65. https://doi.org/10.21037/gs-20-571.PMID:33633972;PMCID:PMC7882347.CrossRefPubMedPubMedCentral

35.

Kogame M, Nagai H, Shinohara M, Igarashi Y, Sumino Y, Ishii K. Th2 dominance might induce carcinogenesis in patients with HCV-related liver cirrhosis. Anticancer Res. 2016;36(9):4529–36. https://doi.org/10.21873/anticanres.11000. (PMID: 27630292).CrossRefPubMed

36.

Matsui T, Nagai H, Sumino Y, Miki K. Relationship of peripheral blood CD4-positive T cells to carcinogenesis in patients with HCV-related chronic hepatitis and liver cirrhosis. Cancer Chemother Pharmacol. 2008;62(3):401–6. https://doi.org/10.1007/s00280-007-0618-1. (Epub 2007 Oct 12 PMID: 17932673).CrossRefPubMed

37.

Lanitis E, Dangaj D, Irving M, Coukos G. Mechanisms regulating T-cell infiltration and activity in solid tumors. Ann Oncol. 2017;28(suppl_12):18–32. https://doi.org/10.1093/annonc/mdx238. (PMID: 29045511).CrossRef

38.

Di Vito C, Mikulak J, Zaghi E, Pesce S, Marcenaro E, Mavilio D. NK cells to cure cancer. Semin Immunol. 2019;41: 101272. https://doi.org/10.1016/j.smim.2019.03.004. (Epub 2019 May 10 PMID: 31085114).CrossRefPubMed

39.

Del Prete A, Sozio F, Barbazza I, Salvi V, Tiberio L, Laffranchi M, Gismondi A, Bosisio D, Schioppa T, Sozzani S. Functional role of dendritic cell subsets in cancer progression and clinical implications. Int J Mol Sci. 2020;21(11):3930. https://doi.org/10.3390/ijms21113930.PMID:32486257;PMCID:PMC7312661.CrossRefPubMedPubMedCentral

Title: Potential prognostic biomarker SERPINA12: implications for hepatocellular carcinoma
Authors: Huan Yang
Panpan Kong
Songyu Hou
Xiaogang Dong
Imamumaimaitijiang Abula
Dong Yan
Publication date: 05-09-2024
Publisher: Springer International Publishing
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Biomarkers
Published in: Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-024-03689-w

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

17-09-2024
Prostate Cancer
News

Adding radium-223 to first-line enzalutamide significantly improves the survival of patients with bone metastatic castration-resistant prostate cancer.

19-09-2024
Diagnostics in Oncology
News

No OS benefit of adding preoperative CRT in gastric cancer

17-09-2024
Gastric Cancer
News

T-DXd supported for breast cancer with brain metastases

17-09-2024
Breast Cancer
News

» View more highlights on the ESMO 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Webinar | 01-10-2024 | 12:30 (CEST)

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Potential prognostic biomarker SERPINA12: implications for hepatocellular carcinoma

Abstract

Background

Methods

Results

Conclusion

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

AI model can predict tumor mutations

No OS benefit of adding preoperative CRT in gastric cancer

T-DXd supported for breast cancer with brain metastases

» View more highlights on the ESMO 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

AI model can predict tumor mutations

No OS benefit of adding preoperative CRT in gastric cancer

T-DXd supported for breast cancer with brain metastases

» View more highlights on the ESMO 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma